Transgene SA, of Strasbourg, France, said the first patient was treated in a phase I/II trial evaluating the combination of oncolytic immunotherapy Pexa-Vec with Opdivo (nivolumab, Bristol-Myers Squibb co.) as a first-line treatment of advanced hepatocellular carcinoma.